KaloBios Pharmaceuticals Inc. started off the year - and the annual J.P. Morgan conference - on a high note, partnering its Humaneered antibody fragment targeted against Pseudomonas aeruginosa infections with Paris-based Sanofi Pasteur in a potential $290 million deal. (BioWorld Today) Read More
